Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly. Trading on the Swedish stock exchange is a smaller Nordic biotech company which has registered a +146% gain on a YTD basis with a market cap of SEK 108m (USD 9.8m).
Still very much a micro-cap, Pila Pharma is a Nordic biotech company listed on the Nasdaq First North exchange in Stockholm. The company was founded by Dorte X. Gram, a former Novo Nordisk researcher who during her time at the company discovered a potential new mechanism of action for the treatment of metabolic diseases.
Pila Pharma went public in the summer of 2021 and has experienced an impressive mark up in its share price throughout 2024, seeing a triple-digit percentage gain from the beginning of the year to now.
Let's take a closer look at the company's main asset.
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
